Active substancePotassium chloride + Calcium chloride + Magnesium chloride + Sodium lactate + Sodium chloride + SorbitolPotassium chloride + Calcium chloride + Magnesium chloride + Sodium lactate + Sodium chloride + Sorbitol
Similar drugsTo uncover
  • Rheosorbylact®
    solution in / in d / infusion 
    YURIYA-FARM, LLC     Ukraine
  • Ringer's lactate with magnesium
    solution in / in d / infusion 
  • Sorbylact®
    solution d / infusion in / in 
    YURIYA-FARM, LLC     Ukraine
  • Dosage form: & nbspsolution for infusions
    Composition:

    In 1 ml of solution contains:

    Active substances: sorbitol - 200.00 mg, sodium lactate - 19.00 mg, sodium chloride - 6.00 mg, calcium chloride in terms of dry matter - 0.1 mg, potassium chloride - 0.3 mg, magnesium chloride in terms of dry matter 0.2 mg. Excipients: water for injection - up to 1 ml.

    Ionic composition of the preparation ......... in mg / ml ................. in mmol / l

    Na+................................................ 6,395....................... 278,16

    K+................................................. 0.157............................ 4.02

    Ca++ ..............................................0.036..............................0,9

    Mg++ .............................................0,051............................ 2,10

    Cl- ................................................ 3,995......................... 112,69

    CH3CH (OH) COO ...................... 15,635 ....................... 175,52

    Theoretical osmolality 1670mOsm / l


    Description:

    clear, colorless liquid.

    Pharmacotherapeutic group:plasma-substituting agent.
    ATX: & nbsp

    B.05.X.A.31   Electrolytes in combination with other drugs

    Pharmacodynamics:

    The drug has anti-shock, energy, detoxifying, alkalinizing, diuretic and stimulating peristalsis of the intestine by action.

    The main pharmacologically active substances are sorbitol (in hypertonic concentration) and sodium lactate (in isotonic concentration). In the liver sorbitol first turns into fructose, which then turns into glucose, and then into glycogen. Part of sorbitol is used for urgent energy needs, the other part is stored as a stock in the form of glycogen. Hypertensive sorbitol solution has a large osmotic pressure and a pronounced ability to enhance diuresis.

    Unlike bicarbonate solution, correction of metabolic acidosis with sodium lactate passes more slowly, as it is included in the metabolism, without causing sharp fluctuations in pH. The effect of sodium lactate is manifested after 20-30 minutes after administration.

    Sodium chloride - plazmozameschayuschee means, shows detoxication, rehydration action, eliminates the deficiency of sodium and chlorine ions in different pathological conditions.

    Calcium chloride eliminates calcium deficiency. Calcium ions are necessary for the implementation of the process of nerve impulse transmission, reduction of skeletal: '% smooth muscle, myocardial activity, bone formation, clotting of blood. Reduces the permeability of cells and the vascular wall, prevents the development of inflammatory reactions, increases the resistance of the body to infections and can significantly enhance phagocytosis.

    Potassium chloride restores the water-electrolyte balance. It shows a negative chrono and batmotroponoe action in high doses - a negative foreign-, dromotropic and mild diuretic effect. Takes part in the process of carrying out nerve impulses. Increases the content of acetylcholine and causes excitation of the sympathetic part of the autonomic nervous system. Improves skeletal muscle contractions in muscular dystrophy, myasthenia gravis.

    Pharmacokinetics:

    Sorbitol quickly enters the general metabolism, 80-90% of which is utilized in the liver and accumulates in the form of glycogen, 5% is deposited in the brain tissues, heart muscle and skeletal muscles, 6-12% is excreted in urine. When sodium lactate is injected into the vascular bed, sodium, CO2 and H2O are released, which form sodium bicarbonate, which leads to an increase in the alkaline reserve of blood. Only half of the sodium lactate injected is considered active (isomer L), and the other half (isomer D) It is not metabolized and excreted in the urine.

    Sodium chloride is rapidly excreted from the vascular bed, only temporarily increasing the volume of circulating blood. Do diuresis.

    Indications:

    Sorbilact® is used to reduce intoxication, improve microcirculation, correct the acid-base state, improve hemodynamics in traumatic, operating, hemolytic and burn shock; peritonitis and intestinal obstruction (in the pre- and postoperative period); with acute renal failure of different etiology; thyrotoxicosis, sepsis; various liver diseases (hepatitis, cholecystitis, acute and subacute liver dystrophies, hepatic coma); increased intracranial pressure in case of cerebral edema.

    Contraindications:

    Individual sensitivity to the components of the drug. Sorbilact® is not used for alkalosis, and in cases when large amounts of fluid are contraindicated (cerebral hemorrhage, thromboembolism, cardiovascular decompensation, arterial hypertension III grade).

    Carefully:

    The drug is prescribed to patients with impaired liver function, peptic ulcer, hemorrhagic colitis.

    Pregnancy and lactation:

    Data on use during pregnancy and breastfeeding are not available.

    Dosing and Administration:

    Sorbilact® is administered to adults by intravenous spray or drip (60-80 drops per minute):

    - in case of traumatic, burn, postoperative and hemolytic shock - 200-400 and 600 ml (3-10 ml / kg body weight), once, first with a stream, then with a drip method;

    - with liver diseases - in a dose of 200 ml (3.5 ml / kg body weight) drip singly and repeatedly, daily or every other day;

    - with acute renal failure - in a single dose of 200-400 ml (up to 2.5-6.5 ml / kg body weight) drip or jet (again after 8-12 hours);

    - for the prevention of postoperative intestinal paresis of 150-300 ml (2.5-5.0 ml / kg body weight) per single injection, drip; repeated infusions of the drug are possible every 12 hours during the first 2-3 days after surgery;

    - for the treatment of postoperative paresis - in a dose of 200-400 ml (3.5-6.5 ml / kg body weight) drip, every 8 hours before the normalization of intestinal motility;

    when swelling of the brain - first jet, and then drip (60-80 drops per minute) at a dose of 5-10 ml / kg body weight.

    With significant dehydration, intravenous infusions of Sorbilact® should be carried out only drip (not more than 200 ml of solution per day).

    Children under the age of 6 years are recommended to administer the drug at a dose of 10 ml / kg of body weight, from 6 to 12 years - in a dose of half the dose for adults. Children over 12 years of age are given the same dose as adults.

    Side effects:There may be phenomena of alkalosis or dehydration (due to hyperosmolarity of the solution), allergic reactions (skin rash, itching).
    Overdose:

    There are phenomena of alkalosis, which quickly pass on their own, provided that the drug is discontinued immediately. When dehydration occurs, symptomatic therapy.

    Interaction:

    Sorbylact® can not be mixed with phosphate- and carbonate-containing solutions. Do not use as a solution carrier for other drugs.

    Special instructions:

    The drug is used under the control of indicators of acid-snibkovogo state and blood electrolytes, as well as the functional state of the liver. With caution apply to patients suffering from calculous cholecystitis. The drug is used, taking into account the osmolarity of blood and urine, as well as the acid-base state. The introduction of sorbilacta® to diabetic patients should be carried out under the control of the sugar content in the blood.

    Effect on the ability to drive transp. cf. and fur:not described
    Form release / dosage:

    Solution for infusion. For 200 or 400 ml of the drug in glass bottles. Each vial Together with the instructions for use are put in a pack of cardboard.

    Packaging:vials (1) -wrapping paper (32)
    vials (1) -wrapping paper (60)
    bottles (1) -tacks, cardboard
    vials (16) -shaped shrink film
    bottles (30) -shaped shrink film
    Storage conditions:

    List B. In a dry, the dark place at a temperature of 2 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:Shelf life. 2 years. Do not use after expiry date.
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-003832/08
    Date of registration:19.05.2008
    The owner of the registration certificate:YURIYA-FARM, LLC YURIYA-FARM, LLC Ukraine
    Manufacturer: & nbsp
    Representation: & nbspYURIYA-FARM LLC YURIYA-FARM LLC Ukraine
    Information update date: & nbsp12.08.2014
    Illustrated instructions
      Instructions
      Up